Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of 19.08 billion. The enterprise value is 15.79 billion.
| Market Cap | 19.08B |
| Enterprise Value | 15.79B |
Important Dates
The next estimated earnings date is Tuesday, February 17, 2026.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 61.60M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.12% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 53.08% |
| Float | 60.88M |
Valuation Ratios
The trailing PE ratio is 12.05 and the forward PE ratio is 22.66.
| PE Ratio | 12.05 |
| Forward PE | 22.66 |
| PS Ratio | 4.96 |
| PB Ratio | 3.32 |
| P/TBV Ratio | 5.23 |
| P/FCF Ratio | 14.36 |
| P/OCF Ratio | 13.94 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.52, with an EV/FCF ratio of 11.88.
| EV / Earnings | 9.97 |
| EV / Sales | 4.08 |
| EV / EBITDA | 10.52 |
| EV / EBIT | 11.06 |
| EV / FCF | 11.88 |
Financial Position
The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.03 |
| Quick Ratio | 6.01 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.11 |
| Interest Coverage | 54.85 |
Financial Efficiency
Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 50.13%.
| Return on Equity (ROE) | 29.41% |
| Return on Assets (ROA) | 13.38% |
| Return on Invested Capital (ROIC) | 50.13% |
| Return on Capital Employed (ROCE) | 22.58% |
| Weighted Average Cost of Capital (WACC) | 8.64% |
| Revenue Per Employee | 1.43M |
| Profits Per Employee | 590,552 |
| Employee Count | 2,681 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 17.23 |
Taxes
In the past 12 months, Genmab has paid 196.37 million in taxes.
| Income Tax | 196.37M |
| Effective Tax Rate | 11.03% |
Stock Price Statistics
The stock price has increased by +67.46% in the last 52 weeks. The beta is 0.79, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +67.46% |
| 50-Day Moving Average | 315.58 |
| 200-Day Moving Average | 237.39 |
| Relative Strength Index (RSI) | 53.13 |
| Average Volume (20 Days) | 6,610 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of 3.85 billion and earned 1.58 billion in profits. Earnings per share was 25.10.
| Revenue | 3.85B |
| Gross Profit | 3.63B |
| Operating Income | 1.42B |
| Pretax Income | 1.78B |
| Net Income | 1.58B |
| EBITDA | 1.47B |
| EBIT | 1.42B |
| Earnings Per Share (EPS) | 25.10 |
Balance Sheet
The company has 3.41 billion in cash and 142.00 million in debt, with a net cash position of 3.27 billion.
| Cash & Cash Equivalents | 3.41B |
| Total Debt | 142.00M |
| Net Cash | 3.27B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.75B |
| Book Value Per Share | 93.41 |
| Working Capital | 3.73B |
Cash Flow
In the last 12 months, operating cash flow was 1.37 billion and capital expenditures -40.38 million, giving a free cash flow of 1.33 billion.
| Operating Cash Flow | 1.37B |
| Capital Expenditures | -40.38M |
| Free Cash Flow | 1.33B |
| FCF Per Share | n/a |
Margins
Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.
| Gross Margin | 94.36% |
| Operating Margin | 36.87% |
| Pretax Margin | 46.28% |
| Profit Margin | 41.17% |
| EBITDA Margin | 38.30% |
| EBIT Margin | 36.87% |
| FCF Margin | 34.54% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.12% |
| Shareholder Yield | 3.12% |
| Earnings Yield | 8.30% |
| FCF Yield | 6.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.17 |
| Piotroski F-Score | 5 |